Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (September 2023)
16 slides from Curis's investor presentation, September 2023
Slide 1: Corporate Presentation
Corporate Presentation NASDAQ: CRIS © 2023 Curis, Inc.
Slide 2: Cautionary Note Regarding Forward Looking Statements and Disclaimers
Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli
Slide 3: Corporate Overview
Corporate Overview Leader of IRAK4 Inhibition in Oncology; Developing Emavusertib with Broad Hematological Applications Investment Emavusertib is a highly-active inhibitor with potential to be the cornerstone agent in hematologic malignancies Thesis Cash runway into 2025 – Proforma cash of $77.4M as
Slide 4: Emavusertib in Leukemia (AML/MDS)
Emavusertib in Leukemia (AML/MDS)
Slide 5: Emavusertib has a Unique Molecular Fingerprint
Emavusertib has A Unique Molecular Fingerprint The NCI selected emavusertib for Targeted design is specifically engineered to be best-in-class NCI-sponsored research and clinical studies of IRAK4 Emavusertib Emavusertib Kinase Interaction Map Binding Affinity FLT3 Target Kd nM IRAK4 IRAK1 12,000 IRA
Slide 6: Emavusertib Has a Unique Mechanism of Action
Emavusertib Has a Unique Mechanism of Action The two primary targets of emavusertib are independent drivers of cancer IRAK4 FLT3 spliceosome mutations drive overexpression of IRAK4-Long, which genetic mutations cause constitutive activation of FLT3 constitutively activates the myddosome, driving NF-
Slide 7: Preclinical Data
Preclinical Data Rationale for monotherapy and combination with azacitidine/venetoclax Monotherapy in IRAK4 Monotherapy in FLT3 Combination with Aza/Ven 100% “Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective means to overcome the adaptive resistance incurred when target
Slide 8: Compelling Initial Clinical Data
Emavusertib Compelling Initial Clinical Data Showing clear single agent activity where expected in clinical studies 84 AML/MDS Patients 8 AML Patients 7 AML Patients all comers, all dose levels Spliceosome Mutation* with FLT3 Mutation* 100% ** ** ** 80% % Change in Marrow Blast from Baseline 0% 0% 6
Slide 9: Potential Cornerstone Treatment for Hematologic Malignancies
Potential Cornerstone Treatment for Hematologic Malignancies Emavusertib inhibits both IRAK4 and FLT3 – key disease drivers in leukemia and lymphoma Monotherapy targets the two Emavusertib synergizes with existing AML/MDS Leukemia largest genetically-defined patient treatments5 as IRAK4-L is express
Slide 10: Emavusertib in Leukemia (AML/MDS)
Emavusertib in Leukemia (AML/MDS) The ideal candidate to address the two largest genetically-defined populations in AML/MDS Emavusertib addresses the two largest genetically-defined populations in AML/MDS: 1 1) IRAK4-L (>50% of population) 2 2) FLT3 (>25% of population) Next Steps TakeAim Leukemia S
Slide 11: Emavusertib in Lymphoma (NHL/CLL)
Emavusertib in Lymphoma (NHL/CLL)
Slide 12: Emavusertib in Lymphoma
Emavusertib in Lymphoma Combination therapy provides complimentary inhibition of two pathways that drive NF-κB NFκB Biology: Clinical Strategy: Two Pathways Drive NHL/CLL Block both pathways with Combination Therapy BCR and TLR Pathways independently drive NF-κB overactivity In preclinical testing,
Slide 13: Initial Clinical Data in Lymphoma
Initial Clinical Data in Lymphoma Majority of patients achieved decreases in tumor burden, including complete responses NHL/CLL 100% Change in Tumor Burden Over Time combination with ibrutinib combination with ibrutinib 80% 60% % Change in Tumor Burden from Baseline 40% 20% BTK-naïve BTK-experienced
Slide 14: Clinical Strategy in Lymphoma
Clinical Strategy in Lymphoma The ideal candidate to combine with BTKi to maximize downregulation of NF-κB • Patients are currently treated with BTKi because it downregulates NF-κB • Two pathways drive NF-κB: Next Steps TakeAim Lymphoma Study 1) BCR Pathway: addressed by blocking BTK 2) TLR Pathway:
Slide 15: Corporate Overview
Corporate Overview Leader of IRAK4 Inhibition in Oncology; Developing Emavusertib with Broad Hematological Applications Investment Emavusertib is a highly-active inhibitor with potential to be the cornerstone agent in hematologic malignancies Thesis Cash runway into 2025 – Proforma cash of $77.4M as
Slide 16: End of Corporate Presentation
End of Corporate Presentation NASDAQ: CRIS